Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999.
about
Laboratory diagnosis and susceptibility profile of Helicobacter pylori infection in the PhilippinesCharacterization and inactivation of an agmatine deiminase from Helicobacter pyloriAntimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States.Antibacterial effects of grape extracts on Helicobacter pyloriNovel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance.Update on the first-line treatment for Helicobacter pylori infection - a continuing challenge from an old enemy.Immunogenicity of Recombinant Helicobacter pylori Urease B Administered by Various Routes and with Different Adjuvants.Clinical Rationale for Confirmation Testing After Treatment of Helicobacter pylori Infection: Implications of Rising Antibiotic Resistance.American College of Gastroenterology guideline on the management of Helicobacter pylori infection.Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori.New strategies for the prevention and treatment of Helicobacter pylori infection.Helicobacter pylori: the challenge in therapy.Helicobacter pylori infection in geriatrics.Rifabutin-based high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pyloriAlaska sentinel surveillance study of Helicobacter pylori isolates from Alaska Native persons from 2000 to 2008High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infectionA randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pyloriHelicobacter pylori detection and antimicrobial susceptibility testing.Multilaboratory comparison of proficiencies in susceptibility testing of Helicobacter pylori and correlation between agar dilution and E test methods.Peptic ulcer and Helicobacter pylori: update on testing and treatment.Trends in the eradication rates of Helicobacter pylori infection for eleven yearsIn vitro effect of amoxicillin and clarithromycin on the 3' region of cagA gene in Helicobacter pylori isolatesIn Vitro and In Vivo Anti-Helicobacter Activities of Eryngium foetidum (Apiaceae), Bidens pilosa (Asteraceae), and Galinsoga ciliata (Asteraceae) against Helicobacter pylori.Assessment of antibacterial effect of garlic in patients infected with Helicobacter pylori using urease breath test.Review article: the global emergence of Helicobacter pylori antibiotic resistance.CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection.Antibiotics resistance of Helicobacter pylori and treatment modalities in children with H. pylori infection.Optimal management of peptic ulcer disease in the elderly.Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough.Therapeutic management of recurrent peptic ulcer disease.Pharmacologic options in the management of upper gastrointestinal bleeding: focus on the elderly.Multiple mutations in or adjacent to the conserved penicillin-binding protein motifs of the penicillin-binding protein 1A confer amoxicillin resistance to Helicobacter pylori.Helicobacter pylori treatment: Still a work in progress.Eradication of Helicobacter pylori Infection.Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012.Helicobacter pylori Clarithromycin Resistance and Treatment Failure Are Common in the USA.A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.Sociodemographic determinants of prevalence and incidence of Helicobacter pylori infection in Portuguese adults.Amoxicillin resistance in Helicobacter pylori: studies from Tokyo, Japan from 1985 to 2003.Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.
P2860
Q24798214-F5468E13-57AA-4FD3-9037-BDA38C6351DCQ27658787-416D9630-3754-414A-9245-4B8A65012792Q30427337-BC77BEEA-5814-4008-93B6-2B8C69FDB311Q33388635-B584005A-A9BC-4E0A-95A2-8A9ADAD0F59FQ33639114-C1C3DBD1-C195-43FF-892C-989CFCC5D4C1Q33893567-CB055B5A-932E-43E6-AB1E-22E90280DC86Q33996971-0FC68BE4-E7C4-4524-9CAE-F0399935FB21Q34448307-48EEF9F4-B4BD-4413-AB11-B61CCB728286Q34645482-FCB2FDA0-8596-4B65-84ED-31BFCBB4EB3CQ34651921-9DC24EC3-4A68-4D84-B3FB-F31EAB88C762Q34768573-992CF87D-645C-43E6-BF54-0F2824BB60CAQ34799596-D09E6160-72B7-4F65-89CB-02DCA3C47560Q34799624-AB222B6C-C0B1-4389-9C1D-EBBF8F8B5A7FQ34823645-EBE86E85-CAE8-4AC6-BA42-7EB2CD3ED34EQ35273580-FE211AF4-D7AB-401F-A64F-2B0BE76045E2Q35498491-8E251C6E-B6AB-41A8-9B2A-EA234EB68129Q35532235-09E55A0D-DB4C-4391-A8F6-7E4E7F741751Q35783436-2A8E267C-C431-4DA0-9CBE-254C5B5B3802Q36047451-40E7B121-5C8B-4C2A-8A37-DB18B567126AQ36185526-F9FE607A-514F-4C11-AF99-0262CA9651A8Q36450494-70EC65D0-EA1F-4CD6-A3F3-CA072B7BD386Q37203555-DC018D7A-84B4-4DD9-9A3E-090BF5AD95B4Q37222948-9B08FCC4-474A-4E3B-BA6B-B80A09CF57F7Q37314363-57A3A7E2-E348-4114-80EA-F4D5C81D32A7Q37340339-051F27D7-C9EF-4E75-B6C4-6B6D04DF72A5Q37646785-F110D5B7-4E9A-433C-8D64-85ED0436BA71Q37663186-C1281A8C-D9AF-4683-9156-DB7395FA1E6BQ37768159-E8D12D21-FE53-4526-9DB7-B6077BBF1B6BQ37948164-2DF621AC-6E5A-4C7A-A7CB-4D0CFFF12FFDQ38032319-CB5D2A4C-4D0B-4B22-9076-27738C38B11BQ38198576-B019C450-D382-46C5-91AD-00CD2CB4405DQ38313492-3FC056F3-DE69-413A-AF16-86E29596C404Q38613590-29D721F3-2C42-46FF-AC56-AD5C6323F79AQ38833959-760370C7-CF57-46E8-929D-3381D3C0A261Q39503264-99796E87-820E-4736-9F30-FA803506608FQ39961975-2DF09751-F8D1-4063-8569-38BC1D0AE6E1Q40093546-667D9CC7-D2F2-4B94-B1CE-E53C9C96345EQ40114688-8B224F81-FBDE-4589-8E8F-64E051696417Q40448487-E4384910-7F24-4903-94BB-14DED9DC1D24Q40572311-DB70BDF9-17B0-4C82-B426-7BF46354CA1F
P2860
Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Risk factors for Helicobacter ...... ship (SHARP) study, 1993-1999.
@en
Risk factors for Helicobacter ...... ship (SHARP) study, 1993-1999.
@nl
type
label
Risk factors for Helicobacter ...... ship (SHARP) study, 1993-1999.
@en
Risk factors for Helicobacter ...... ship (SHARP) study, 1993-1999.
@nl
prefLabel
Risk factors for Helicobacter ...... ship (SHARP) study, 1993-1999.
@en
Risk factors for Helicobacter ...... ship (SHARP) study, 1993-1999.
@nl
P2093
P921
P1476
Risk factors for Helicobacter ...... ship (SHARP) study, 1993-1999.
@en
P2093
David Morris
Eileen C King
Helen Bhattacharyya
Jennifer E Sugg
Joette M Meyer
Nancy P Silliman
Nancy Y Siepman
Robert J Hopkins
Wenjin Wang
P356
10.7326/0003-4819-136-1-200201010-00008
P407
P577
2002-01-01T00:00:00Z